DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02647853 (ClinicalTrials.gov)	October 2014	3/1/2016	Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers	A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel	Nasolabial Folds;Lipoatrophy;Lipodystrophy	Drug: TAT4 Gel concentration A;Drug: TAT4 Gel concentration B;Drug: Placebo	Topokine Therapeutics, Inc.	NULL	Completed	40 Years	70 Years	Both	16	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

October 2014

3/1/2016

Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers

A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel

Nasolabial Folds;Lipoatrophy;Lipodystrophy

Drug: TAT4 Gel concentration A;Drug: TAT4 Gel concentration B;Drug: Placebo

Topokine Therapeutics, Inc.

NULL

Completed

40 Years

70 Years

Both

Phase 1

United States